The challenges of in silico contributions to drug metabolism in lead optimization

Bibliography

• Williams PA, Cosme J, Ward Sridhar V, Johnson EF. Mammalian microsomal cytochrome P450 monooxygenase: structural Adaptations for Membrane Binding and Functional Diversity. Struct Mol Cell 2000;5:121-31
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Ward A, Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003;424:464-8
   PubMed Web of Science ®Google Scholar
• Langowski J, Long A. Computer systems for the prediction of xenobiotic metabolism. Adv Drug Deliv Rev 2002;54:407-15
   PubMed Web of Science ®Google Scholar
• Kulkarni SA, Zhu J, Blechinger S. In silico techniques for the study and prediction of xenobiotic metabolism: a review. Xenobiotica 2005;35:955-73
   PubMed Web of Science ®Google Scholar
• Ridder L, Wagener M. SyGMa: combining expert knowledge and empirical scoring in the prediction of metabolites. ChemMedChem 2008;3:821-32
   PubMed Web of Science ®Google Scholar
• Czodrowski P, Kriegl JM, Scheuerer S, Fox T. Computational approaches to predict drug metabolism. Expert Opin Drug Metab Toxicol 2009;5:15-27
   PubMed Web of Science ®Google Scholar
• Borodina Y, Sadym A, Filimonov D, Predicting biotransformation potential from molecular structure. J Chem Inf Comput Sci 2003;43:1636-46
   PubMedGoogle Scholar
• Boyer S, Arnby CH, Carlsson L, Reaction site mapping of Xenobiotic biotransformations. J Chem Inf Mod 2007;47:583-90
   PubMed Web of Science ®Google Scholar
• Smith J, Stein V. SPORCalc: a development of database analysis that provides putative metabolic enzyme reactions for ligand-based drug design. Comp Biol Chem 2009;33:149-59
   PubMed Web of Science ®Google Scholar
• Boyer S, Zamora I. New methods in predictive metabolism. J Comp-Aid Drug Des 2002:16:403-13
   Web of Science ®Google Scholar
• Rydberg P, Vasanthanathan P, Oostenbrink C, Olsen L. Fast prediction of cytochrome P450 mediated drug metabolism. ChemMedChem 2009;4:2070-9
   PubMed Web of Science ®Google Scholar
• De Graaf C, Vermulen NPE, Feenstra KA. Cytochrome P450 in Silico: an integrative modeling approach. J Med Chem 2005;48:2725-55
   PubMed Web of Science ®Google Scholar
• Jones JP, Mysinger M, Korzekwa KR. Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab Disp 2002;30:7-12
   PubMed Web of Science ®Google Scholar
• De Graaf C, Oostenbrink C, Keizers PHJ, Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking J Med Chem 2006;49:2417-30
   PubMed Web of Science ®Google Scholar
• Vasannthanathan P, Hritz J, Taboureau O, Virtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands. J Chem Inf Model 2009;49:43-52
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Vinkovic DM, Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone, Science 2004;305:683-6
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 2004;279:38091-4
   PubMed Web of Science ®Google Scholar
• Ekroos M, Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 2006;103:13682-7
   PubMed Web of Science ®Google Scholar
• Gopaul VS, Shin Y, Le H, Comparing StarDrop vs. MetaSite prediction of sites of metabolism by CYP3A4, CYP2C9 and CYP2D6: application of in silico tools in drug discovery metabolite identification studies. Poster at meeting of the international society for the study of Xenobiotics (ISSX); Baltimore; 2009
   Google Scholar
• Cruciani G, Carosati E, Boeck BD, MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist J Med Chem 2005;48:6970-9
   PubMed Web of Science ®Google Scholar
• Singh SB, Shen LQ, Walker MJ, Sheridan RP. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 2003;46:1330-6
   PubMed Web of Science ®Google Scholar
• Sheridan RP, Korzekwa KR, Torres RA, Walker MJ. Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. J Med Chem 2007;50:3173-84
   PubMed Web of Science ®Google Scholar
• Rydberg P, Gloriam DE, Zaretzki J, SMARTCyp: A 2D method for prediction of cytochrome P450-mediated drug metabolism. ACS Med Chem Lett 2010, available on-line pre-publication (exact information to be entered after it is available)
   Google Scholar
• Oh W-S, Kim D-N, Jung J, New combined model for the prediction of regioselectivity in cytochrome P450/3A4 mediated metabolism. J Chem Inf Model 2008;48:591-601
   PubMed Web of Science ®Google Scholar
• Kim D-N, Cho K-H, Oh W-S, EaMEAD: activation energy prediction of cytochrome P450 mediated metabolism with effective atomic descriptors. J Chem Inf Model 2009:49:1643-54
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Ackland MJ, Horne VA, A novel approach to predicting P450 mediated drug metabolism.CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 1999;42:4062-70
   PubMed Web of Science ®Google Scholar
• de Groot MJ, Alex AA, Jones BC. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem 2002;45:1983-93
   PubMed Web of Science ®Google Scholar
• Afzelius L, Arnby CH, Broo A, State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistic insights, and future applications. Drug Metab Rev 2007;39:61-86
   PubMed Web of Science ®Google Scholar
• Zhou D, Afzelius L, Grimm SW, Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab Disp 2006;34:976-83
   PubMed Web of Science ®Google Scholar
• See documentation for the current version of MetaSite which has the third component used in the prediction. Available from: http://www.moldiscovery.com/docs/metasite/background.html#REACTION.MECHANISM.COMPONENT
   Google Scholar
• Zhang Z, Zhu M, Tang W. Metabolite identification and profilling in drug design: current practice and future directions. Curr Pharm Des 2009;15:2235
   Google Scholar
• Nassar A-EF, Talaat RE. Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Disc Today 2004;9:317-27
   PubMed Web of Science ®Google Scholar
• Remmel RP, Crews BC, Kozak KR, Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor, indomethacin phenethylamide in rat, mouse and human liver microsomes: identification of active metabolites. Drug Metab Disp 2004;32:113-22
   PubMed Web of Science ®Google Scholar
• Boyer D, Bauman JN, Walker DP, Utility of metasite in improving metabolic stability of the neutral indomethacin amide derivative and selective cycloexygenase-2 inhibitior 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-inol-3-yl)-N-phenethyl-acetamide. Drug Metab Disp 2009;37:999-1008
   PubMed Web of Science ®Google Scholar
• Trunze M, Faller B, Zimmerlin A. Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation. J Med Chem 2009;52:329-5
   PubMed Web of Science ®Google Scholar
• Ahlstrom MM, Ridderstrom M, Zamora I, Luthman K. CYP2C9 Structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitiors. J Med Chem 2007;50:4444-52
   PubMed Web of Science ®Google Scholar
• Ahlstrom MM, Ridderstrom M, Zamora I. CYP2C9 Structure-metabolism relationships: substrates, inhibitors and metabolites. J Med Chem 2007;50:5382-91
   PubMed Web of Science ®Google Scholar
• Tandon M, O'Donnell M-M, Porte A, The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorg Med Chem Lett 2004;14:1709-12
   PubMed Web of Science ®Google Scholar
• Fisher MB, Henne KR, Boer J. The complexities inherent in attempts to decrease drug clearance by blocking the site of CYP-mediated Metabolism. Curr Opin Drug Disc Dev 2006;9:101-9
   PubMed Web of Science ®Google Scholar
• Muller K, Faeh C, Diedrich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 2007;317:1881-6
   PubMed Web of Science ®Google Scholar
• Shah P, Westwell AD. The role of fluorine in medicinal chemistry. J Enz Inh Med Chem 2007;22:527-40
   PubMed Web of Science ®Google Scholar
• Mutlib AE. Application of stable isotope-labeled compounds in metabolism and in metabolism-mediated toxicity studies. Chem Res Tox 2008;17:1672-89
   Google Scholar
• Park BK, Kitteringham NR, O'Neill PM. Metabolism of fluorine-containing drugs. Ann Rev Pharmacol Toxicol 2001;41:443-70
   PubMed Web of Science ®Google Scholar
• Morgenthaler M, Schweizer E, Hoffmann-Rcder A, Predicting and tuning physicochemical properties in lead optimization: amine basicities. ChemMedChem 2007;2:1100-15
   PubMed Web of Science ®Google Scholar
• Scarfe GB, Tugnait M, Wilson ID, Nicholson JK. Studies on the metabolism of 4-fluoroaniline and 4-fluoroacetanilide in rat: formation of 4-acetamidophenol (paracetamol) and its metabolites via defluorination and N-acetylation. Xenobiotica 1999;29:205-16
   PubMed Web of Science ®Google Scholar
• Chen H, Shockcor J, Chen W, Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR. Chem Res Tox 2002;15:388-99
   PubMed Web of Science ®Google Scholar
• Samuel K, Yin W, Stearns RA, Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom 2003;38:211-21
   PubMed Web of Science ®Google Scholar
• Zhang D, Krishan R, Wang L, Metabolism, pharmacokinetics and protein covalent binding of radiolabeled maxipost (BMS-204352) in humans. Drug Metab Disp 2005;33:83-93
   PubMed Web of Science ®Google Scholar
• Koerts J, Soffers AEMF, Vervoort J, Occurrence of the NIH Shift upon the cytochrome P450-Catalyzed in vivo and in vitro aromatic ring hydroxylations of fluorbenzenes. Chem Res Tox 1998:11:503-12
   PubMed Web of Science ®Google Scholar
• Dear GJ, Ismail IM, Mutch PJ, Urinary metabolites of a novel quinoxaline non-nucleoside reverse trabscriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS. Xenobiotica 2000;30:407-26
   PubMed Web of Science ®Google Scholar
• Guroff G, Daly JW, Jerina DM, Hydroxylation-induced migration: the NIH Shift. Science 1967;157:1524-30
   PubMed Web of Science ®Google Scholar
• For more information, see http://www.schrodinger.com
   Google Scholar
• Fishelovitch D, Hazan C, Shaik S, Structural dynamics of the cooperative binding of organic molecules in the human cytochrome P450 3A4. J Am Chem Soc 2007;129:1502-11
   PubMedGoogle Scholar
• Khan KK, You QH, Domanski TL, Halpert JR. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharamcol 2002;61:495-506
   PubMed Web of Science ®Google Scholar